A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Canada

Kriya Clinical Study Site, Ottawa, Ontario

New Zealand

Kriya Clinical Study Site, Christchurch